Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy
- PMID: 34260829
- DOI: 10.1111/aos.14957
Monitoring intraocular proangiogenic and profibrotic cytokines within 7 days after adjunctive anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy
Abstract
Purpose: To monitor the intraocular proangiogenic and profibrotic cytokine profiles within 7 days after intravitreous injection of conbercept (IVC) for patients with proliferative diabetic retinopathy (PDR).
Methods: This prospective, randomized controlled, consecutive, comparative study included 157 eyes with PDR. Participant eyes underwent sham IVC or IVC and subsequent vitrectomy at days 2, 3, 4, 5, 6, 7 postinjection. The intraocular cytokines profiles were measured using beaded assay methods.
Results: After IVC, the vascular endothelial growth factor (VEGF)-A level in PDR vitreous decreased rapidly by approximately 10 times at day 2 (p = 0.00001) and kept at a low level at days 3, 4, 5, 6, 7 (p < 0.001, each compared with IVC-sham group). Similar tendency of the change in VEGF-A was observed in aqueous humour. The level of placenta growth factor (PIGF) in aqueous humour decreased 2 days after IVC whereas returned to baseline level after 5 days. The vitreous profibrotic cytokines, tissue growth factor (TGF)-β1, TGF-β2, TGF-β3 and connective tissue growth factor did not increase after IVC in each group.
Conclusion: We observed a remarkable and rapid decrease in intraocular VEGF-A, temporal decrease in PIGF from day 2 to day 4, increase in VEGF-C and VEGF-D from day 2 onwards, but no profibrotic switch in PDR eyes after IVC. The findings might suggest that ideal vitrectomy timing might be around 3 days after IVC.
Keywords: PIGF; VEGF; anti-VEGF; aqueous humour; conbercept; cytokines; proliferative diabetic retinopathy; vitrectomy; vitreous.
© 2021 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Similar articles
-
Vascular endothelial growth factor concentration in vitreous humor of patients with severe proliferative diabetic retinopathy after intravitreal injection of conbercept as an adjunctive therapy for vitrectomy.Chin Med J (Engl). 2020 Mar 20;133(6):664-669. doi: 10.1097/CM9.0000000000000687. Chin Med J (Engl). 2020. PMID: 32068603 Free PMC article. Clinical Trial.
-
Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.Graefes Arch Clin Exp Ophthalmol. 2022 Jun;260(6):1899-1906. doi: 10.1007/s00417-021-05515-3. Epub 2022 Jan 14. Graefes Arch Clin Exp Ophthalmol. 2022. PMID: 35028761
-
Intraocular pharmacokinetics of anti-vascular endothelial growth factor agents by intraoperative subretinal versus intravitreal injection in silicone oil-filled eyes of proliferative diabetic retinopathy: a randomized controlled pilot study.Acta Ophthalmol. 2020 Nov;98(7):e795-e800. doi: 10.1111/aos.14386. Epub 2020 Feb 29. Acta Ophthalmol. 2020. PMID: 32114709
-
Network meta-analysis of intravitreal conbercept as an adjuvant to vitrectomy for proliferative diabetic retinopathy.Front Endocrinol (Lausanne). 2023 Feb 22;14:1098165. doi: 10.3389/fendo.2023.1098165. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36896181 Free PMC article. Review.
-
Changes in aqueous and vitreous inflammatory cytokine levels in nonproliferative diabetic retinopathy: systematic review and meta-analysis.Can J Ophthalmol. 2025 Feb;60(1):e100-e116. doi: 10.1016/j.jcjo.2024.05.031. Epub 2024 Jul 21. Can J Ophthalmol. 2025. PMID: 39043257
Cited by
-
Comparison of the adjuvant effect of conbercept intravitreal injection at different times before vitrectomy for proliferative diabetic retinopathy.Front Endocrinol (Lausanne). 2023 May 26;14:1171628. doi: 10.3389/fendo.2023.1171628. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37305048 Free PMC article.
-
Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy.Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4. Cochrane Database Syst Rev. 2023. PMID: 37260074 Free PMC article. Review.
-
Intravitreal conbercept injection with panretinal photocoagulation for high-risk proliferative diabetic retinopathy with vitreous hemorrhage.Int J Ophthalmol. 2024 Jun 18;17(6):1066-1072. doi: 10.18240/ijo.2024.06.11. eCollection 2024. Int J Ophthalmol. 2024. PMID: 38895681 Free PMC article.
-
Vitreous Inflammatory Cytokines and Chemokines, Not Altered After Preoperative Adjunctive Conbercept Injection, but Associated With Early Postoperative Macular Edema in Patients With Proliferative Diabetic Retinopathy.Front Physiol. 2022 Mar 3;13:846003. doi: 10.3389/fphys.2022.846003. eCollection 2022. Front Physiol. 2022. PMID: 35309074 Free PMC article.
-
Effect of Intravitreal Conbercept Injection on Complications of Pars Plana Vitrectomy in Patients with Proliferative Diabetic Retinopathy.J Pers Med. 2023 Mar 23;13(4):572. doi: 10.3390/jpm13040572. J Pers Med. 2023. PMID: 37108958 Free PMC article.
References
-
- Aleman I, Castillo Velazquez J, Rush SW & Rush RB (2019): Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial. Br J Ophthalmol 103: 1740-1746.
-
- Arevalo JF, Maia M, Flynn H et al. (2008): Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92: 213-216.
-
- Bressler SB, Liu D, Glassman AR et al. (2017): Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab. JAMA Ophthalmol 135: 558-568.
-
- Castillo J, Aleman I, Rush SW & Rush RB (2017): Preoperative bevacizumab administration in proliferative diabetic retinopathy patients undergoing vitrectomy: a randomized and controlled trial comparing interval variation. Am J Ophthalmol 183: 1-10.
-
- Chelala E, Nehme J, El Rami H, Aoun R, Dirani A, Fadlallah A & Jalkh A (2018): Efficacy of intravitreal ranibizumab injections in the treatment of vitreous hemorrhage related to proliferative diabetic retinopathy. Retina (Philadelphia Pa.) 38: 1127-1133.
Publication types
MeSH terms
Substances
Grants and funding
- 2017YFA0104101/Key Project of Research and Development Plan of Hunan Province
- 81900875/National Natural Science Foundation of China
- 81870669/National Natural Science Foundation of China
- 81770973/National Natural Science Foundation of China
- 12027808/Special-funded Program on National Key Scientific Instruments and Equipment Development
LinkOut - more resources
Full Text Sources
Medical